TP53 and cancer: iASPP is often overexpressed in cancers, promoting drug resistance and a poor prognosis by stabilizing and activating antioxidant nuclear factor erythroid 2-related factor 2 (NRF2) independently of cellular tumor antigen p53 (P53) [69].